Open and transparent ? Read our concerns over the WHO Expert Working Group process
Treating Too Few, Too Late Read about the case for starting ARV treatment earlier in developing countries click here
An ideal TB test ? Read interview with Access Campaign director
Job openings at the Campaign We are looking for a Medical Innovation Policy Adviser and an EU Policy Advocacy Assistant Read more
|
 |
|
 |
|
 |
Calling all governments: Put patients’ needs first.
MSF Medical Coordinator, Liesbet Ohler talks of Charles, a two year-old child whose death she couldn’t prevent because of ineffective or unadapted tools for TB, for HIV and particularly for children. Click here
Dying for a test: breaking the cycle of neglect
Access Campaign biologist Martine Usdin answers questions on TB diagnostics: what are the problems with the tests today? Are they suited to HIV/TB or drug-resistance? What do the tests of the future need to look like? What needs to happen so that those tests can be developed? Click here
Is Aids a neglected disease?
MSF HIV doctor Alexandra Calmy explains why despite all the research that goes on in the West, the needs of HIV patients in developing countries, in particular women and children, go largely unanswered. She tells what the IGWG about R&D and access to antiretrovirals. Click here
Falling through the cracks: working to fight Chagas disease with limited tools
MSF doctors in Bolivia answer our questions: why is detecting and treating Chagas so difficult? How do you make do with tests and drugs that are worth using, but not nearly safe or effective enough to accept as the only option? What needs to change? Click here
'Outrageous' cost of medicine condemns patients to blindness
MSF's Dr.Peter Saranchuk talks about MSF’s attempts to save patients’ sight or life by treating CMV in China. Affordable treatment for CMV retinitis exists, but involves injecting patients directly into the eyes. Better treatments are too expensive – US$10,000 per patient course – and Roche’s offer for lower prices come with too many strings attached. Click here
Click here 
to read the full document including essays on alternative methods of stimulating R&D for diseases that mainly affect people in developing countries
